Insmed (NSM) Doses First Patient in ARIKACE Phase 2
Insmed Incorporated (Nasdaq: INSM), announced that the first patient has been dosed in the Company's U.S. phase 2 clinical study of ARIKACE® (liposomal amikacin for inhalation) in patients with non-tuberculous mycobacterial (NTM) lung disease entitled TARGET-NTM (Treatment with ARIKACE to Realize Greater Efficacy Trial).
You May Also Be Interested In
- BioSpecifics (BSTC) Reports First Dosing in Phase 2 of CCH (AUXL)
- MFC Industrial (MIL) Will Support Kellogg Nominees for Termination of Proxy Contest
- St. Jude (STJ) Receives CE Mark for 25 mm Portico Transcatheter AHVIS
Create E-mail Alert Related CategoriesCorporate News, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!